Loading…
← CockpitCompetitor Analysis › 688319.SS Chengdu Olymvax Biopharmaceuticals Inc. Class AOpen in the cockpit ↗

Chengdu Olymvax Biopharmaceuticals Inc. Class A688319.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.

Momentum neutral 45
Mkt cap
$1.51B
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$15.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.4 pp
WACC 11.5%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥24.71
1D-1.5%
1W-12.4%
1M-8.6%
3M-11.7%
6M-37.0%
YTD-2.6%
1Y+9.5%
ATR %5.8%
52w lowhigh45.0% off high

What Chengdu Olymvax Biopharmaceuticals does

Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

Moat: none

Headquarters: Chengdu, China · Employees: 451

Chengdu Olymvax Biopharmaceuticals at a glance

Size Chengdu Olymvax Biopharmaceuticals (688319.SS) is a China Health Care company (Biotechnology) with a market value of $1.51B, the 1507th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.71 on 18 Nov 2026.

Performance Over six months the shares fell 37.0%, against -2.8% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 12.3% over the last twelve months (peer median +25.4%); the operating margin is 8.2% (peer median -9.6%).

Valuation It trades at 13.1× enterprise value to sales against a peer median of 10.1× (8th most expensive of 18).

Capital Return on invested capital runs 5.4 points below its cost of capital (11.5% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 100688319.SS 62
Six months, rebased to 100: Chengdu Olymvax Biopharmaceuticals against the median of its 20 peers (local-currency closes).

Chengdu Olymvax Biopharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥796MCN¥702MCN¥587MCN¥494MCN¥544M
Revenue growth—+19%+19%-9%—
Gross profitCN¥746MCN¥624MCN¥532MCN¥443MCN¥488M
EBITDAn/aCN¥76.0MCN¥57.4MCN¥37.6MCN¥43.3M
Net income-CN¥32.0MCN¥22.3MCN¥20.8MCN¥17.6MCN¥26.6M
Free cash flow-CN¥106MCN¥7.18M-CN¥216M-CN¥125M-CN¥222M
Capital expenditureCN¥125MCN¥98.8MCN¥207MCN¥170MCN¥201M
Total debtCN¥509MCN¥433MCN¥362MCN¥238MCN¥139M

Quarterly statements and history in the cockpit →

Chengdu Olymvax Biopharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%KRSAKLRAPGEN087010MSBNRIX2637URGN688765VIR688105QUREPPGNABSI6949688222ALVOANIP688319.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Chengdu Olymvax Biopharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×1,500×KRSAPGEN087010MSBNRIXURGN688765VIRIMCRABSI6949688319.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chengdu Olymvax Biopharmaceuticals is the large dot.

Chengdu Olymvax Biopharmaceuticals competitors and peer comparison

How Chengdu Olymvax Biopharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chengdu Olymvax Biopharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure688319.SSPeer medianRank in peer set
1-month return-8.6%-10.9%9th highest of 21
6-month return-37.0%-2.8%4th lowest of 20
Distance from 52-week high-45.0%-42.7%10th lowest of 21
Revenue growth (TTM)+12.3%+25.4%6th lowest of 19
Operating margin8.2%-9.6%7th highest of 19
EV / Sales13.1×10.1×8th most expensive of 18
ROIC minus cost of capital-5.4 pp-15.4 pp6th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%

Questions

Which companies are Chengdu Olymvax Biopharmaceuticals's closest peers?
The cockpit's peer set: Korsana Biosciences (KRSA), TLC BioSciences (7924.TWO), Kailera Therapeutics (KLRA), Precigen (PGEN), Peptron (087010.KS), Mesoblast (MSB.AX), Nurix Therapeutics (NRIX), Fujian Haixi Pharmaceuticals (2637.HK).
Is Chengdu Olymvax Biopharmaceuticals expensive compared with its peers?
On ev / sales it trades at 13.1× against a peer median of 10.1×, 8th most expensive of 18 in its peer set.
How has Chengdu Olymvax Biopharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -37.0% against -2.8% for the median peer; over one year +9.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.